GRAIL, Inc. reported a total revenue of $36.2 million for the third quarter of 2025, marking a 26% increase from $28.7 million in the same period last year. The growth was primarily driven by a 29% rise in screening revenue, which reached $32.8 million, attributed to a 39% increase in the volume of Galleri tests sold. However, the average selling price (ASP) for these tests decreased by 7%. For the nine months ending September 30, 2025, total revenue was $103.6 million, up 19% from $87.3 million in the prior year, with screening revenue contributing $96.3 million, a 25% increase year-over-year.
Despite the revenue growth, GRAIL reported a net loss of $89.0 million for the third quarter, an improvement from the $125.7 million loss recorded in the same quarter of 2024. For the nine-month period, the net loss was $309.2 million, significantly lower than the $1.9 billion loss reported in the previous year, which included substantial impairment charges. The company’s operating expenses totaled $161.5 million for the quarter, down from $212.2 million a year earlier, reflecting cost-cutting measures and a restructuring plan aimed at focusing resources on its core multi-cancer early detection business.
In terms of operational metrics, GRAIL has sold approximately 420,000 Galleri tests since its launch, with over 128,000 sold in the first nine months of 2025 alone. The company has expanded its network of prescribers to over 16,000 across the United States. GRAIL's workforce has also been streamlined, with a reduction of approximately 30% in headcount as part of its restructuring efforts, which were completed in late 2024.
Looking ahead, GRAIL has entered into a strategic collaboration with Samsung, which includes a $110 million equity investment to support the commercialization of Galleri in Korea and potentially other Asian markets. Additionally, the company completed a private placement financing round that raised approximately $325 million, which will be used to fund its commercial activities and working capital needs. GRAIL anticipates that its existing cash and marketable securities, totaling $540.1 million as of September 30, 2025, will be sufficient to meet its operational needs for at least the next 12 months. The company is also preparing for a premarket approval submission to the FDA for Galleri, expected in early 2026, which could further enhance its market position.
About GRAIL, Inc.
GRAIL, Inc. develops multi-cancer early detection (MCED) blood tests, primarily through its Galleri platform, to identify over 50 cancer types at early stages. Its products aim to complement existing screening guidelines, improve early diagnosis, and reduce cancer mortality. The company leverages proprietary methylation technology, extensive clinical data, and strategic partnerships to expand access, gain regulatory approval, and establish a new standard in population-wide cancer screening.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.